At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 41 enrolled
Drug / intervention
Creon® +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-blind, Randomized, Multicenter, Cross-over Study to Compare the Effect of Creon N and Creon® on Fat Digestion in Subjects ≥ 12 Years of Age With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis
In Brief
A Phase 3 clinical trial evaluating Creon® and Creon N for Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis. Completed, enrolled 41 participants across 7 sites in 2 countries.
Detailed Summary
maldigestion of dietary macronutrients (pancreas not producing enough enzymes for digestion of fat, sugars and proteins) in Cystic Fibrosis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesHungary, Spain
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartJan 2014
First PostedMay 2014
Primary CompletionAug 2014
TodayJul 2026
First PostedMay 13, 2014
Enrollment StartJan 1, 2014
Primary CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 12.1 years ago
Interventions
Creon®drug
active comparator
Creon Ndrug
experimental drug